Distributed Technologies Research Simplifies Global Payments
11.12.2024 10:00:00 CET | Business Wire | Press release
Introduces Revolutionary B2B Payment Solutions
Distributed Technologies Research (DTR), a fintech company focused on simplifying global payments infrastructure, officially launched its technology platform today. DTR seamlessly bridges national payment systems around the world to make financial transactions efficient, secure and universally accessible.
Current payment networks suffer from inefficiencies – such as transfer costs, interchange fees, FX conversion charges, settlement delays and other opaque fees – that effectively act as an indirect tax on consumers worldwide. DTR’s innovative solutions mitigate these inequities with an adaptable, compliant and scalable payment systems architecture that is globally accessible to businesses of all sizes.
“Our team has spent several years studying the systemic barriers within traditional payment systems. The amalgamation of national payments systems with blockchain technologies has the potential to eliminate the hidden tax on consumers,” said Akshay Naheta, Founder & CEO of DTR.
DTR has unveiled AmalgamOS™, a state-of-the-art technology stack designed to streamline money transfers and merchant payments. Leveraging its proprietary International Orchestration Network (ION), AmalgamOS™ enhances financial connectivity and security for businesses worldwide. Currently live and trusted by numerous merchants and corporate clients, AmalgamOS™ enables instant fiat-to-fiat, fiat-to-stablecoin and stablecoin-to-fiat transactions in over 40 countries, with a roadmap into more than 100 countries in 2025.
Key Features of AmalgamOS™:
Enhanced Transaction Speed: Transactions settle in minutes, leveraging blockchains’ 24/7 operational capability.
Cost Efficiency: Reduced reliance on intermediaries drastically lowers transaction fees.
Global Reach: Currently operational for payouts in over 40 countries worldwide, with pay-in capabilities available across EU nations. The platform is consistently expanding, with new countries being added monthly to enhance global reach and accessibility.
Developer-Centric Design: Flexible API’s, easy-to-integrate widgets, comprehensive white-label solutions, and a merchant control panel provide extensive optionality through simple integrations.
DTR’s interdisciplinary team combines seasoned professionals from traditional finance, payment systems, blockchains and Web3 technology. “DTR is dedicated to its goal of redefining the payments ecosystem by fostering inclusivity and eliminating inefficiencies, benefitting millions of people worldwide. By leveraging blockchain technologies for transparency, security and instantaneous settlements, DTR is addressing the growing demand for efficient and scalable payments solutions,” said Naheta.
Stablecoin transaction volume reached $8.5 trillion(1) in the second quarter of 2024 alone, and the global cross-border payments market is projected to grow to $290 trillion by 2030 from $190 trillion in 2023(2). DTR is uniquely positioned to lead this global payment systems transformation.
About Distributed Technologies Research (DTR)
Distributed Technologies Research (DTR) is at the forefront of simplifying how businesses conduct secure and seamless money transfers globally. We connect disparate national payment networks to enable a worldwide, instantaneous payments ecosystem. Our proprietary AmalgamOS™ technology and International Orchestration Network (ION) provide next-generation payments infrastructure and solutions.
For more information, visit http://www.dtr.org/
About Akshay Naheta, Founder & CEO, DTR
Akshay Naheta founded DTR with a vision to simplify financial transactions through the creation of an advanced global payments infrastructure. He brings over 20 years of experience in finance and technology, with an intricate understanding of blockchains, financial markets and payment systems. Previously, he held senior executive roles at SoftBank Group, where he spearheaded numerous technology investments in industry leaders such as ARM, Auto1 and Nvidia.
Sources:
(1) a16z, State of Crypto Report 2024. https://tinyurl.com/yn9wwjzj
(2) FTX Intelligence, Cross-border payments market sizing data. https://tinyurl.com/bdr7nkdv
View source version on businesswire.com: https://www.businesswire.com/news/home/20241210988080/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom